000			01993 a2200589 4500
005			20250517122316.0
264		0	_c20180611
008			201806s 0 0 eng d
022			_a1437-7799
024	7		_a10.1007/s10157-016-1348-7 _2doi
040			_aNLM _beng _cNLM
100	1		_aMorisawa, Norihiko
245	0	0	_aUsefulness of combination therapy with Daclatasvir plus Asunaprevir in chronic hepatitis C patients with chronic kidney disease. _h[electronic resource]
260			_bClinical and experimental nephrology _cOct 2017
300			_a818-824 p. _bdigital
500			_aPublication Type: Journal Article; Observational Study
650	0	4	_aAged
650	0	4	_aAged, 80 and over
650	0	4	_aAntiviral Agents _xadverse effects
650	0	4	_aCarbamates
650	0	4	_aDrug Therapy, Combination
650	0	4	_aFemale
650	0	4	_aGenotype
650	0	4	_aGlomerular Filtration Rate
650	0	4	_aHepacivirus _xdrug effects
650	0	4	_aHepatitis C, Chronic _xcomplications
650	0	4	_aHumans
650	0	4	_aImidazoles _xadverse effects
650	0	4	_aIsoquinolines _xadverse effects
650	0	4	_aJapan
650	0	4	_aKidney _xphysiopathology
650	0	4	_aLongitudinal Studies
650	0	4	_aMale
650	0	4	_aPyrrolidines
650	0	4	_aRNA, Viral _xblood
650	0	4	_aRenal Insufficiency, Chronic _xcomplications
650	0	4	_aRetrospective Studies
650	0	4	_aSulfonamides _xadverse effects
650	0	4	_aSustained Virologic Response
650	0	4	_aTime Factors
650	0	4	_aTreatment Outcome
650	0	4	_aValine _xanalogs & derivatives
650	0	4	_aViral Load
700	1		_aKoshima, Yohei
700	1		_aSatoh, Jun-Ichi
700	1		_aMaruyama, Yukio
700	1		_aKuriyama, Satoru
700	1		_aYokoo, Takashi
700	1		_aAmemiya, Morimasa
773	0		_tClinical and experimental nephrology _gvol. 21 _gno. 5 _gp. 818-824
856	4	0	_uhttps://doi.org/10.1007/s10157-016-1348-7 _zAvailable from publisher's website
999			_c26542069 _d26542069